BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 23885174)

  • 1. The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluation.
    Yu KF; Zhang WQ; Luo LM; Song P; Li D; Du R; Ren W; Huang D; Lu WL; Zhang X; Zhang Q
    Int J Nanomedicine; 2013; 8():2473-85. PubMed ID: 23885174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor effect of iRGD-modified liposomes containing conjugated linoleic acid-paclitaxel (CLA-PTX) on B16-F10 melanoma.
    Du R; Zhong T; Zhang WQ; Song P; Song WD; Zhao Y; Wang C; Tang YQ; Zhang X; Zhang Q
    Int J Nanomedicine; 2014; 9():3091-105. PubMed ID: 25028548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comprehensive study of iRGD-modified liposomes with improved chemotherapeutic efficacy on B16 melanoma.
    Dai W; Fan Y; Zhang H; Wang X; Zhang Q; Wang X
    Drug Deliv; 2015 Jan; 22(1):10-20. PubMed ID: 24735248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cellular toxicity and anti-tumor efficacy of iRGD modified doxorubixin loaded sterically stabilized liposomes].
    Zhao B; Fan YC; Wang XQ; Dai WB; Zhang Q; Wang XL
    Yao Xue Xue Bao; 2013 Mar; 48(3):417-22. PubMed ID: 23724658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced intracellular uptake of sterically stabilized liposomal Doxorubicin in vitro resulting in improved antitumor activity in vivo.
    Xiong XB; Huang Y; Lu WL; Zhang H; Zhang X; Zhang Q
    Pharm Res; 2005 Jun; 22(6):933-9. PubMed ID: 15948037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic.
    Xiong XB; Huang Y; Lu WL; Zhang X; Zhang H; Nagai T; Zhang Q
    J Control Release; 2005 Oct; 107(2):262-75. PubMed ID: 16125816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does ligand-receptor mediated competitive effect or penetrating effect of iRGD peptide when co-administration with iRGD-modified SSL?
    Zhang WQ; Yu KF; Zhong T; Luo LM; Du R; Ren W; Huang D; Song P; Li D; Zhao Y; Wang C; Zhang X
    J Drug Target; 2015 Dec; 23(10):897-909. PubMed ID: 26087869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo.
    Xiong XB; Huang Y; Lu WL; Zhang X; Zhang H; Nagai T; Zhang Q
    J Pharm Sci; 2005 Aug; 94(8):1782-93. PubMed ID: 15986461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. iNGR-Modified Liposomes for Tumor Vascular Targeting and Tumor Tissue Penetrating Delivery in the Treatment of Glioblastoma.
    Zhou JE; Yu J; Gao L; Sun L; Peng T; Wang J; Zhu J; Lu W; Zhang L; Yan Z; Yu L
    Mol Pharm; 2017 May; 14(5):1811-1820. PubMed ID: 28388081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide.
    Chen X; Wang X; Wang Y; Yang L; Hu J; Xiao W; Fu A; Cai L; Li X; Ye X; Liu Y; Wu W; Shao X; Mao Y; Wei Y; Chen L
    J Control Release; 2010 Jul; 145(1):17-25. PubMed ID: 20307599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Physicochemical Property of iRGD Peptide Modified Doxorubicin Loaded Liposome and Its Effect on Cancer Cell Growth].
    Zhang ZQ; Zhong CL; Zhao X
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2015 Nov; 46(6):837-41. PubMed ID: 26867317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel octreotide modified lipid vesicle improved the anticancer efficacy of doxorubicin in somatostatin receptor 2 positive tumor models.
    Zhang J; Jin W; Wang X; Wang J; Zhang X; Zhang Q
    Mol Pharm; 2010 Aug; 7(4):1159-68. PubMed ID: 20524673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies.
    Zhang YF; Wang JC; Bian DY; Zhang X; Zhang Q
    Eur J Pharm Biopharm; 2010 Mar; 74(3):467-73. PubMed ID: 20064608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The co-delivery of a low-dose P-glycoprotein inhibitor with doxorubicin sterically stabilized liposomes against breast cancer with low P-glycoprotein expression.
    Gao W; Lin Z; Chen M; Yang X; Cui Z; Zhang X; Yuan L; Zhang Q
    Int J Nanomedicine; 2014; 9():3425-37. PubMed ID: 25092974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coadministration of Oligomeric Hyaluronic Acid-Modified Liposomes with Tumor-Penetrating Peptide-iRGD Enhances the Antitumor Efficacy of Doxorubicin against Melanoma.
    Deng C; Zhang Q; Fu Y; Sun X; Gong T; Zhang Z
    ACS Appl Mater Interfaces; 2017 Jan; 9(2):1280-1292. PubMed ID: 28009503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell-penetrating corosolic acid liposome as a functional carrier for delivering chemotherapeutic drugs.
    Li X; Widjaya AS; Liu J; Liu X; Long Z; Jiang Y
    Acta Biomater; 2020 Apr; 106():301-313. PubMed ID: 32081779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-tumor and anti-angiogenic effect of metronomic cyclic NGR-modified liposomes containing paclitaxel.
    Luo LM; Huang Y; Zhao BX; Zhao X; Duan Y; Du R; Yu KF; Song P; Zhao Y; Zhang X; Zhang Q
    Biomaterials; 2013 Jan; 34(4):1102-14. PubMed ID: 23127332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The antitumor activity of tumor-homing peptide-modified thermosensitive liposomes containing doxorubicin on MCF-7/ADR: in vitro and in vivo.
    Wang C; Wang X; Zhong T; Zhao Y; Zhang WQ; Ren W; Huang D; Zhang S; Guo Y; Yao X; Tang YQ; Zhang X; Zhang Q
    Int J Nanomedicine; 2015; 10():2229-48. PubMed ID: 25834435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prednisolone phosphate‑induced suppression of the angiogenic function of tumor‑associated macrophages enhances the antitumor effects of doxorubicin on B16.F10 murine melanoma cells in vitro.
    Licarete E; Rauca VF; Luput L; Patras L; Sesarman A; Banciu M
    Oncol Rep; 2019 Dec; 42(6):2694-2705. PubMed ID: 31578578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The reduction of tumor interstitial fluid pressure by liposomal imatinib and its effect on combination therapy with liposomal doxorubicin.
    Fan Y; Du W; He B; Fu F; Yuan L; Wu H; Dai W; Zhang H; Wang X; Wang J; Zhang X; Zhang Q
    Biomaterials; 2013 Mar; 34(9):2277-88. PubMed ID: 23290525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.